YOU ARE INVITED TO DISCOVER A NEW APPROACH TO NEURODEGENERATION AT OUR LABS IN CULHAM SCIENCE CENTRE
ON MARCH 30th
• Explore the possibility of collaborative projects
• Discuss opportunities of industrial experience for early stage researchers.
• Challenge existing theories and approaches to neurodegeneration
Neuro-Bio (www.neuro-bio.com) is a privately held company taking a new approach to neurodegenerative disorders such as Alzheimer’s Disease.
Building on 40 years of original research initially at Oxford University, and now based at the Culham Science Centre, we research a novel signaling molecule (a peptide ‘T14’) significantly elevated in Alzheimer’s brains and driving the cycle of brain cell death in selectively vulnerable cells.
Neuro-Bio is developing a system for detection of T14 as a companion blood biomarker for early diagnosis of neuro-degenerative disorders along with novel drug candidates that could constitute a completely different type of drug to actually halt the neurodegenerative process.
The company has a pipeline of future products that includes other indications such as Parkinson’s and Motor Neuron Disease. Following on from a recent transition to Series A funding we are welcoming further collaborations on proof of concept, biomarker validation, animal models and testing of therapeutic candidates.
Our in-house techniques include: Biomarker in human samples, secondary drug screening in cell cultures and tertiary screening by using a state-of-the art imaging technique of voltage-sensitive dye imaging in brain slices.